CSCIF COSCIENS Biopharma Inc. IFRS
Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-21.8%
TTM net income YoY32.3%
TTM EPS YoY44.9%
Revenue 3-yr CAGR-19.9%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-142.5%
Net margin-138.1%
FCF margin-122.4%
EBITDA margin-126.6%
Returns
ROE-121.8%
ROA-36.7%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets82.1%
Debt / equity0.00x
Current ratio3.18x
Interest coverage-63.58x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue9.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.50M | $9.59M |
| Cost of revenue | $4.85M | $4.86M |
| Gross profit | $2.65M | $4.73M |
| R&D expense | $2.95M | $8.30M |
| SG&A expense | $10.06M | $10.45M |
| Operating income | -$10.68M | -$18.28M |
| Interest expense | $168,000 | $129,000 |
| Pretax income | -$10.35M | -$15.22M |
| Income tax | $10,000 | $84,000 |
| Net income | -$10.36M | -$15.31M |
| EBITDA | -$9.49M | -$16.67M |
| EPS (basic) | -3.27 | -5.93 |
| EPS (diluted) | -3.27 | -5.93 |
| Weighted avg. shares (diluted) | 3.17M | 2.58M |
| Balance sheet | ||
| Cash & equivalents | $7.31M | $16.39M |
| Receivables | $1.26M | $2.36M |
| Inventory | $1.31M | $2.69M |
| Current assets | $11.50M | $23.98M |
| PP&E, netmay include right-of-use assets (IFRS) | $9.81M | $10.97M |
| Total assets | $21.43M | $35.07M |
| Current liabilities | $3.61M | $7.22M |
| Total liabilities | $17.59M | $21.91M |
| Shareholders' equity | $3.84M | $13.16M |
| Cash flow statement | ||
| Operating cash flow | -$8.47M | -$14.57M |
| Capital expenditure | $706,000 | $1.16M |
| Free cash flow | -$9.18M | -$15.73M |
| Investing cash flow | -$458,000 | $25.08M |
| Financing cash flow | -$407,000 | -$588,000 |
| Depreciation & amortization | $1.19M | $1.61M |
| Stock-based compensation | -$12,000 | $464,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.